Linee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
|
|
- Walter Owen
- 6 years ago
- Views:
Transcription
1 Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, Marzo 2014
2 Clinical guidelines are only one option for improving the quality of care. Clinical guidelines make sense when practitioners are unclear about appropriate practice and when scientific evidencecanprovideananswer.theyareapoorremedyin other settings. When clinicians already know the information contained in guidelines, should redirect their efforts to identify the specific barriers, beyond knowledge, that stand in the way of behavior change. SH Woolf et al., BMJ 1999
3 Current treatment Algorithm for mrcc therapy HISTOLOGY SETTING RISK GROUP STANDARD THERAPY OPTION Clear-cell Favourable/Inter mediate risk Sunitinib (Motzer, NEJM 2007) Bevacizumab+ INFa (Escudier, Lancet 2007) Pazopanib (Sternberg, J Clin Oncol 2010) Cytokine(IL-2HD) Sorafenib I Line Poor-risk Temsirolimus (Hudes, NEjM 2007) Sunitinib Sorafenib II Line Post cytokines Sorafenib ( Escudier, NEJM 2007) Pazopanib Axitinib (Rini, Lancet 2011) Sunitinib Post TKIs Everolimus (Motzer, Lancet, 2008) Axitinib (Rini, Lancet 2011) Sorafenib Non clear-cell Clinical trial Temsirolimus Ciccarese C, Massari F Sunitinib Sorafenib
4 First-line treatment for clear cell mrcc: guidelines Favourable and Intermediate risk AIOM 1 ESMO 2 NCCN 3 EAU 4 Sunitinib (pos. forte) Bevacizumab + IFNα (pos. debole) Sunitinib (IA) Bevacizumab + IFNα (IA)* Sunitinib (cat.1) Bevacizumab + IFNα (cat.1) Sunitinib (1b) Bevacizumab + IFNα (1b) Pazopanib (pos. debole) Pazopanib (IIB)* Pazopanib (cat.1) Pazopanib (1b) Sorafenib IL-2 High-dose IL-2 Temsirolimus Sorafenib Clinical trial IL-2 Poor risk Temsirolimus (pos. debole) Temsirolimus (IA)* Temsirolimus (cat.1) Temsirolimus (1b) Sunitinib 1 Linee GuidaAIOM 2013; 2 Escudier B, et al. Ann Oncol NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer v ; 4 Ljungberg B, et al. 2013; *Corrigendum Ann Oncol 24(6): vi171, 2013
5 First-line treatment for clear cell mrcc: AIOM guidelines AIOM guidelines 2013
6 First-line treatment for clear cell mrcc: AIOM guidelines Modified by R. Passalacua, AIOM guidelines 2013
7 Bevacizumab + Interferon-α in 1st-line
8 Why choosing Sunitinib? Progression-free survival probability Hazard Ratio=0.538 (95% CI 0.439, 0.658) p< IFN-α Median 5.1 months (95% CI ) Time (months) Sunitinib Median 11.0 months (95% CI ) No. at Risk Sunitinib: IFN-α: Level of evidence: 1; grade of recommendation: A Motzer RJ et al., NEJM 2007
9 Sunitinib works in all risk groups Risk Group* % Median PFS (months) Sunitinib (n=375) IFN-a (n=375) Favorable (0 risk factor) (95% CI) ( ) ( ) Intermediate (1-2 risk factors) (95% CI) ( ) ( ) Poor ( 3 risk factors) (95% CI) ( ) ( ) *Motzer et al. J Clin Oncol 2002;20:289-96; Risk factors associated with shorter survival were: low hemoglobin, high corrected calcium, high LDH, poor performance status, and an interval of <1 yr from diagnosis to treatment Motzer RJ, et al., NEJM 2007
10 Why choosing Pazopanib? Proportion Progression-Free Pazopanib Placebo Months Hazard Ratio = % CI (0.34, 0.62) P value < Median PFS Pazopanib: 9.2 mo Placebo: 4.2 mo Sternberg, J Clin Oncol 2010
11 First-line treatment for clear cell mrcc: AIOM guidelines AIOM guidelines 2013
12 COMPARZ Trial: Study design Phase 3, randomized, noninferiority trail, designed to compared the efficacy and safety of pazopanib and sunitinib in patients with mrcc as first-line treatment. KEY ELIGIBILITY CRITERIA: Advanced or metastatic RCC Clear-cell histologic component No prior systemic therapy Measurable disease KPS >70 Adequate organ function Stratification Factors: KPS 70/80 vs 90/100 Prior nephrectomy Baseline LDH R A N D O M I Z E 1 : 1 PAZOPANIB 800 mg/qd continuous dosing Dose reductions to 600 mg or 400 mg SUNITINIB 50 mg qd 4wk on/2wk off Dose reductions to 37.5 mg or 25 mg 1100 pts (183 asiatics) Motzer RJ et al., NEJM 2013; 369(8):
13 COMPARZ TRIAL: EFFICACY RESULTS PAZOPANIB SUNITINIB HR Median PFS (IRC) 8.4 months 9.5 months Median OS* 28.4 months 29.3 months (95%CI ) (95%CI ) ORR (IRC) 31% 25% p=0.032 Median duration of the treatment 8 months 7.6 months Dose reductions 44% 51% Discontinuations due toaes 24% 19% * Interim analysis Motzer RJ et al. ESMO 2012 (abst.lba8) -Motzer RJ et al., NEJM 2013; 369(8):
14 COMPARZ has changed the guidelines? EscudierB, et al. Ann Oncol2012 ; Corrigendum Ann Oncol24(6): vi171, 2013
15 COMPARZ has changed the guidelines? EAU 2013 EAU 2010 LjungbergB, et al. 2013; LjungbergB, et al. 2010
16 Phase 3 Trial Temsirolimus in Poor-risk mrcc HudesG et al. N EngJ Med. 2007
17 Temsirolimus: Overall Survival HudesG et al. N EngJ Med. 2007
18 Current treatment Algorithm for mrcc therapy HISTOLOGY SETTING RISK GROUP STANDARD THERAPY OPTION Clear-cell Favourable/Inter mediate risk Sunitinib (Motzer, NEJM 2007) Bevacizumab+ INFa (Escudier, Lancet 2007) Pazopanib (Sternberg, J Clin Oncol 2010) Cytokine(IL-2HD) Sorafenib I Line Poor-risk Temsirolimus (Hudes, NEjM 2007) Sunitinib Sorafenib II Line Post cytokines Sorafenib ( Escudier, NEJM 2007) Pazopanib Axitinib (Rini, Lancet 2011) Sunitinib Post TKIs Everolimus (Motzer, Lancet, 2008) Axitinib (Rini, Lancet 2011) Sorafenib Non clear-cell Clinical trial Temsirolimus Ciccarese C, Massari F Sunitinib Sorafenib
19 Current treatment Algorithm for mrcc therapy II Line Post cytokines Sorafenib ( Escudier, NEJM 2007) Pazopanib Axitinib (Rini, Lancet 2011) Sunitinib Post TKIs Everolimus (Motzer, Lancet, 2008) Axitinib (Rini, Lancet 2011) Sorafenib Ciccarese C, Massari F. 2013
20 Second-line treatment for clear cell mrcc: guidelines Second-line after TKI AIOM 1 ESMO 2 NCCN 3 EAU 4 Everolimus (pos. forte) Sorafenib (pos. debole) Axitinib(IB)* Everolimus(IIA) Axitinib(cat.1) Everolimus(cat.1) Sorafenib(cat.2) Sunitinib(cat.2) Axitinib(1b) Everolimus(1b) Sorafenib(1b) Seond-line after cytokines Sorafenib (pos. forte) Pazopanib (pos. debole) Sunitinib (pos. debole) Axitinib(IA) Sorafenib(IA) Pazopanib(IIA) Sunitinib(IIIA) Axitinib(cat.1) Sorafenib(cat.1) Pazopanib(cat.1) Sunitinib(cat.1) Axitinib(1b) Sorafenib(1b) Pazopanib(1b) 1 Linee Guida AIOM 2013; 2 Escudier B, et al. Ann Oncol NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer v ; 4 Ljungberg B, et al. 2013; *Corrigendum Ann Oncol 24(6): vi171, 2013
21 Second-line treatment for clear cell mrcc: AIOM guidelines Modified by R. Passalacua, AIOM guidelines 2013
22 Everolimus has level I evidence in 2 nd line
23 RECORD-1: Everolimus vs. placebo Patientswith: Metastatic RCC with clear cell component; Measurable disease; Progressive disease on or within 6 months of treatment with sunitinib, sorafenib, or both; Prior bevacizumab and cytokines permitted; Adequate performance status, blood counts, and serum chemistry. R 2:1 Everolimus 10 mg/day. Treat until PD, unmanageable AEs or withdrawal of consent. Stratification factors: Prior VEGFrTKI: 1 or 2 MSKCC risk group: favorable, intermediate, or poor Placebo N=362 Primary endpoint: PFS Secondary endpoints: OS, ORR, safety, QoL 1. Motzer, et al. Lancet 2008;372:449-56; 2. Motzer et al. Cancer 2010;116:
24 RECORD-1: Everolimus vs. placebo Progression Free Survival Overall Survival 81% of pts crossed over from pbo to everolimus. 1. Motzer, et al. Lancet 2008;372:449-56; 2. Motzer et al. Cancer 2010;116:
25 RECORD-1: a real II line trial? (more than 75% of pts in RECORD-1 received everolimus as 3rd+ Line) 1 st Line 2 nd Line 3 rd Line mtor 4 th Line n = 82 5 th Line 1 st Line 2 nd Line 3 rd Line mtor 4 th Line n = % 1 st Line 2 nd Line mtor 3 rd Line n = st Line mtor 2 nd Line n = 89 21% Patients received a median of 2 prior antineoplastic medications 1. Motzer, et al. Lancet 2008;372:449-56; 2. Motzer et al. Cancer 2010;116: ; 3. Calvo E, et al. Eur J Cancer 2011.
26 Axitinib has level I evidence in 2 nd line
27 AXIS Trial: Axitinib vs. Sorafenib Patientswith mrcc and PD Histologically-confirmedmRCC with clear-cell component Failure of prior first-line regimen containing 1 of: -Sunitinib - Bevacizumab +IFN-α - Temsirolimus - Cytokine(s) Stratification factors: Prior regimen ECOG PS (0 vs 1) R 1:1 Axitinib 5 mg b.i.d. Sorafenib 400 mg oral BID (n=253) N=723 Treat until PD, unmanageable AEs or withdrawal of consent. Primary endpoint: PFS Secondary endpoints: OS, ORR, safety, QoL Motzer RJ et al. Lancet Oncol 2013
28 AXIS Trial: Axitinib vs. Sorafenib PFS in overall population PFS in Sunitinibpretreated population Rini BI et al. Lancet Oncol 2011
29 AXIS Trial: Axitinib vs. Sorafenib OS in overall population OS in Sunitinibpretreated population Crossover from sorafenib to axitinib was not allowed. Motzer RJ et al. Lancet Oncol 2013
30 Sorafenib has now level I evidence in 2 nd line, too
31 INTORSECT Trial: Temsirolimus vs. Sorafenib PatientswithmRCC and PD on 1 st line sunitinib(n=512) Stratification factors: Durationofsunitinib therapy( or >6 mo) MSKCC riskgroup Histology(clear cell or non-clear cell) Nephrectomy status R 1:1 Temsirolimus 25 mg IV weekly (n=259) Sorafenib 400 mg oral BID (n=253) Treat until PD, unacceptable toxicity, or discontinuation for any other reason N=512 Primary endpoint: PFS Secondary endpoints: OS, ORR, duration of response, safety, QoL HutsonTE, et al. JClinOncol. 2013
32 INTORSECT Trial: Temsirolimus vs. Sorafenib Hutson T, ESMO 2012
33 Current treatment Algorithm for mrcc therapy HISTOLOGY SETTING RISK GROUP STANDARD THERAPY OPTION Clear-cell Favourable/Inter mediate risk Sunitinib (Motzer, NEJM 2007) Bevacizumab+ INFa (Escudier, Lancet 2007) Pazopanib (Sternberg, J Clin Oncol 2010) Cytokine(IL-2HD) Sorafenib I Line Poor-risk Temsirolimus (Hudes, NEjM 2007) Sunitinib Sorafenib II Line Post cytokines Sorafenib ( Escudier, NEJM 2007) Pazopanib Axitinib (Rini, Lancet 2011) Sunitinib Post TKIs Everolimus (Motzer, Lancet, 2008) Axitinib (Rini, Lancet 2011) Sorafenib Non clear-cell Clinical trial Temsirolimus Ciccarese C, Massari F Sunitinib Sorafenib
34 Current treatment Algorithm for mrcc therapy Non clear-cell Clinical trial Temsirolimus Sunitinib Sorafenib Ciccarese C, Massari F. 2013
35 nccrcc Treatment Options Are Limited Efficacy and safety data are inconclusive Patients usually excluded from pivotal trials 1 No targeted therapies currently approved for nccrcc Evidence-based treatment guidelines are limited 2,3,4 Clear guidance is lacking; optimal treatment strategy remains to be determined 5 1. Schrader AJ et al. BJU Int. 2008;101: NCCN. Clinical Practice Guidelines in Oncology for Kidney Cancer. V Escudier B et al. Ann Oncol. 2012; 4. Ljungberg B et al. Eur Urol. 2013; 5. Singer EA et al. Target Oncol. 2010;5:
36 Conclusion and open questions Limit of Guidelines which refer to studies very selected in terms of methodology, inclusion and exclusion criteria Discrepancies in guidelines: how to assess them? In what may be useful and how we can use them in clinical practice? Where there are many differences in efficacy or toxicity there is no question, but where the results are similar or almost similar?
37
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More informationDose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring
Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring Alison Zhang 1, Peter Fox 1, Sally Coulter 4, Val Gebski 5, Bavanthi Balakrishnar 1, Christopher Liddle
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationTreatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationWhat can we expect from running phase III trials: will all of them alter the current treatment algorithm?
What can we expect from running phase III trials: will all of them alter the current treatment algorithm? 8 th European International Kidney Cancer Symposium Budapest, May 2013 Martin Gore PhD FRCP Royal
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationPrognostic Factors for mrcc: Relevance in Clinical Practice
Prognostic Factors for mrcc: Relevance in Clinical Practice Daniel Heng MD MPH FRCPC Chair, GU Tumor Group Tom Baker Cancer Center University of Calgary Prognostic Factors Patient Factors Performance Status
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationRenal Cell Carcinoma
Renal Cell Carcinoma Sequencing in renal cancer: two options for the same problem (TKImTOR) Viktor Grünwald Clinic for Hematology, Hemostasis, Oncology and Stemcelltransplantation Prof. Viktor Grünwald
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationAxitinib in renal cell carcinoma: now what do we do?
Renal Cell Carcinoma Axitinib in renal cell carcinoma: now what do we do? Ian D. Davis Monash University Eastern Health Clinical School, Level 2, Box Hill, Victoria 3128, Australia Correspondence to: Ian
More informationHow does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy
How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Targeting VHL/HIF in Clear Cell RCC VHL Bevacizumab (Antibody)
More informationPrognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationRenal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland
Renal Cell Cancer Clinical case study 1 & 2 Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland 1 Case study 1 - RCC and Lung Metastases Case study 1: Patient History Male, 63 years old Mild
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationThe Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations
Evidence-Based Series #3-8-4: Section 1 The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations S. Hotte, T. Waldron,
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE
Tivozanib Hydrochloride in Advanced Renal Cell Carcinoma ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE AVEO PHARMACEUTICALS, INC. 75 Sidney Street Cambridge, MA 02139 Tel: (617) 299-5000
More informationProspettive future nel trattamento medico del mrcc. Francesco Massari Oncologia Medica Policlinico S Orsola-Malpighi Bologna
Prospettive future nel trattamento medico del mrcc Francesco Massari Oncologia Medica Policlinico S Orsola-Malpighi Bologna 3 rd YOUNG SPECIALIST RENAL CARE Firenze, 09 Aprile 2016 Renal cell carcinoma
More informationOpinion 26 June 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 26 June 2013 VOTRIENT 200 mg, film-coated tablets B/30 (CIP: 491 313 4) VOTRIENT 400 mg, film-coated tablets B/30
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationCarcinoma renale. Francesco Atzori. Oncologia Medica Azienda Ospedaliero Universitaria Cagliari. Posters & Oral abstracts
Carcinoma renale Posters & Oral abstracts Francesco Atzori Oncologia Medica Azienda Ospedaliero Universitaria Cagliari Milano 3 marzo 2017 Renal Cell Cancer Track 2017 Genitourinary Cancers Symposium Poster
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationCLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12
Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationCANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /
CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationReference No: Author(s) Approval date: June Committee. Operational Date: July Review:
Reference No: Title: Author(s) Systemic anti-cancer therapy (SACT) guidelines for renal cell cancer Dr Alison Clayton Consultant Medical Oncologist & Dr Jane Hurwitz Consultant Medical Oncologist, Cancer
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationA Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Kim et al. BMC Urology (2016) 16:46 DOI 10.1186/s12894-016-0163-5 RESEARCH ARTICLE Open Access A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationRevisione Oral Abstracts
Revisione Oral Abstracts Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi UPDATES and NEWS from the Genitourinary Cancers Symposium - Milano,
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More informationComplete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy
Complete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy Is complete remission an achievable goal in mrcc? Lessons from observation Lessons from immunotherapy Current status in
More informationClick to edit Master /tle style. Cardiovascular Toxicity in Renal Cell Carcinoma Pa/ents
Click to edit Master /tle style Cardiovascular Toxicity in Renal Cell Carcinoma Pa/ents Bernhard J. Eigl MD FRCPC Medical Oncologist, BC Cancer Agency Clinical Associate Professor, University of Bri/sh
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationWhy was HOPE 205 a Positive After Years of Negative Studies?
Why was HOPE 205 a Positive After Years of Negative Studies? Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Why do we pursue combinations?
More informationFeasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
Koie et al. BMC Urology (2015) 15:32 DOI 10.1186/s12894-015-0027-4 RESEARCH ARTICLE Open Access Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationManagement del paziente dializzato Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
Management del paziente dializzato Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena AIOM incontra SIN Milano 9 marzo 2017 Renal Cell Carcinoma and Renal Impairment Up to 15% of
More informationTherapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 2275-2280, 2015 Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis QINXIANG TAN 1*,
More informationAtezolizumab Adjuvant Study: Medical Oncologist Perspective. Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center
Atezolizumab Adjuvant Study: Medical Oncologist Perspective Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center Trial overview Key issues Outline Challenges with neoadjuvant therapy Placebo control
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationIntroduction. pissn , eissn Cancer Res Treat. 2014;46(4):
pissn 1598-2998, eissn 2005-9256 Original Article http://dx.doi.org/10.4143/crt.2013.154 Open Access Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
into consideration the concerns of the patient. Upon reconsideration of the perc Initial Recommendation,the Committee discussed feedback from the patient advocacy group reporting concerns that the definition
More informationINTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA
INTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA Dr. Michael J. Metcalfe PGY-4 Department of Urologic Sciences University of British Columbia October
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationIntegration of Surgery And Systemic Therapy In The Treatment of
Integration of Surgery And Systemic Therapy In The Treatment of Advanced Renal Cell Carcinoma Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Professorship In Urology
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationEfficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.5.1971 Efficacy and Toxicity of Sunitinib in Egyptian Patients with Metastatic Renal Cell Carcinoma RESEARCH ARTICLE Efficacy and Toxicity of Sunitinib in Metastatic
More informationRenal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto)
Renal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Nimira Alimohamed (Staff Medical Oncologist, University of Calgary)
More informationEuropean consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
More informationAlternativas de Futuro en Cáncer Renal Enrique Grande
Alternativas de Futuro en Cáncer Renal Enrique Grande Hospital Ramón y Cajal de Madrid The ncreasingly Challenging Field of mrcc Sorafenib (US 2005, EU 2006) 3,4 Sunitinib (US & EU 2006) 3,4 Early 1940s:
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationESMO Madrid, Spain Associate Professor Brian Costello Division of Medical Oncology, Genitourinary Tumour Group, Mayo Clinic, USA
ESMO 2017 - Madrid, Spain Associate Professor Brian Costello Division of Medical Oncology, Genitourinary Tumour Group, Mayo Clinic, USA HIGHLIGHTS ON RENAL CELL CARCINOMA CHECKMATE 214: EFFICACY AND SAFETY
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationWhen to Treat Beyond Progression with Systemic Therapies? Manuela Schmidinger Medical University of Vienna, Austria
When to Treat Beyond Progression with Systemic Therapies? Manuela Schmidinger Medical University of Vienna, Austria Is Treatment Beyond Progression a Valid Strategy? 1) NO YES? Is Treatment Beyond Progression
More informationImproving our understanding of papillary renal cell carcinoma with integrative genomic analysis
Perspective Page 1 of 5 Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis Parth K. Modi 1, Eric A. Singer 1,2 1 Division of Urology, Rutgers Robert Wood Johnson
More informationWill All Adjuvant Therapy Trials Be Negative in RCC?
Will All Adjuvant Therapy Trials Be Negative in RCC? Tim Eisen Eleventh European International Kidney Cancer Symposium 29-30 April 2016 Crowne Plaza Barcelona Fira Center, Barcelona, Spain Tim Eisen -
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More information